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ABSTRACT
Fighting against pathogenic bacteria that are resistant to antibiotics has become critical for health care worldwide. More than half 
a million people die every year from infections caused by drug resistant bacteria. Since bacteria acquire resistance to antibiotics 
very quickly and the development of new antibiotics is a lengthy process, the search for new approaches to stop the spread of bac-
terial resistance is extremely important. The spread of antibiotic resistance is accomplished mainly by horizontal gene transfer. 
Scientists are concentrating their efforts on studying the mechanism of this process in order to find a way to stop or reverse it. In 
this paper, the author gives a brief review of the recent studies on horizontal gene transfer, particularly on incompatibility-based 
plasmid curing systems. The author examines new possibilities to use the mechanism of horizontal gene transfer for the develop-
ing of novel approaches to fight pathogenic bacteria.
INTRODUCTION
The emergence of multidrug resistant bacteria that are 
not susceptible to known antibiotics is one of the most 
important and urgent problems of modern health care 
worldwide. According to Lord Jim O’Neill’s report pub-
lished in 2016 [1], by the year 2050 the lives of about 
10  million people a year will be at risk from infections 
caused by multidrug resistant (MDR) bacteria if scientists 
will not come up with a breakthrough in developing new 
antimicrobials and/or new methods to fight pathogenic 
bacteria. Even nowadays, 700,000 people worldwide die 
from infections with MDR bacteria. Not the entire sci-
entific community agrees with this particular prediction 
[2], but scientists and doctors all over the world consider 
bacterial resistance as one of the greatest threats to pub-
lic health. 
The first examples of bacterial resistance were ob-
served by Alexander Fleming who discovered the first 
antibiotic penicillin. Many antibiotics are produced by 
microorganisms including bacteria – natural antibiot-
ics  – and the bacteria-producers are not killed by the 
antibiotic that they produce. These bacteria use special 
mechanisms in certain life cycle processes that make 
them resistant to the action of the antibiotics that they 
produce. Thus, the bacteria that produce antibiotics 
were probably the first examples of bacteria with anti-
biotic resistance. Antibiotic resistance mechanisms can 
be divided into two categories: general and more specif-
ic. One of the examples of general antibiotic resistance 
mechanisms is the efflux of different antibiotics from the 
bacterial cell by efflux pumps. This leads to the rapid de-
crease of the concentration of an antibiotic in the bacte-
rial cell and ensures the survival of the bacteria. Another 
general mechanism of resistance is the deactivation of 
an antibiotic in the bacterial cell by enzymatic hydroly-
sis, acylation, phosphorylation etc., although for every 
antibiotic the reaction is accomplished with a specific 
enzyme. Specific mechanisms of resistance include the 
modification of the structure of the antibiotic target in 
bacteria, e.g. ribosome and synthesis of short peptides 
that prevent the efficient interaction of an antibiotic 
with its target in the bacterial cell. In the course of natu-
ral selection, according to the Charles Darwin theory of 
evolution, bacteria can become resistant to a certain an-
tibiotic as a result of the corresponding gene mutations. 
Both pathogenic and non-pathogenic bacteria acquire 
resistance to natural as well as to synthetic antibiotics by 
means of natural selection and this resistance is passed 
to the offspring (vertical gene transfer). 
Another mechanism of the emergence of bacterial 
resistance is horizontal gene transfer (HGT) [3-5]. Ac-
cording to the modern concept of HGT, it includes vari-
ous mechanisms that could be broadly divided into three 
categories: transduction (transfer of genetic material by 
means of phages), conjugation (transfer of genetic mate-
rial on plasmids from the donor bacterium to the recipi-
ent bacterium usually through the pili), and transforma-
tion (adsorption of genetic material by bacteria from the 
environment) [6, 7]. Fast spreading of beneficial genetic 
information by means of HGT between bacteria helps 
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them to survive in a changing ecological environment 
in nature. This mechanism is also successfully used by 
bacteria for defense from antibiotics. By rapid exchange 
with plasmids that contain antibiotic resistance genes, 
the pathogenic bacteria survive treatment with antibi-
otics that leads to the deterioration and even death of 
infected patients. Some of those plasmids contain genes 
that make bacteria resistant to several antibiotics – mul-
tidrug resistant bacteria – making them the most danger-
ous type of pathogenic bacteria. Since the development 
of new antibiotics in the US from the beginning of the 
discovery process to FDA approval, production launch, 
and start of marketing takes about 16-17 years and costs 
around $1.75 billion [8] while bacterial resistance to the 
new antibiotic can develop in the course of several days 
[9], it is clear that we are losing the fight against patho-
genic bacteria. Therefore, the search for new approaches 
to stop the spreading of bacterial resistance and to kill 
the pathogenic bacteria is one of the most important di-
rections in life sciences.
Since HGT is the main mechanism of the spreading 
of bacterial resistance, lately it has become the subject 
of intensive research [6, 7, 10-13]. It is believed that the 
processes of plasmid transfer from the donor bacterium 
to recipient bacterium (Fig. 1) as well as the maintaining 
of the received plasmid in bacterium are associated with 
significant fitness costs [14], although not all scientists 
agree with that conclusion [15]. 
Recently, it was shown that the plasmid transfer be-
tween bacteria intensifies in the presence of stress fac-
tors like certain metal salts, UV light, small concentra-
tions of antibiotics and/or toxins, etc. [16]. It should be 
mentioned that many antibiotic resistance plasmids 
contain a so-called ‘addictive’ system – genes that en-
code for long living toxins and short living antitoxins. 
Bacteria containing this kind of plasmid cannot lose it 
since it would then be killed by the toxin. On the other 
hand, this toxin-antitoxin addictive system ensures that 
the plasmid will be copied in the course of the cell divi-
sion and that the offspring bacterial cell will contain the 
copy of this plasmid [17-19]. 
In general, the more we learn about HGT the more we 
understand that it is a very complicated process that de-
pends on a number of factors, such as the conditions in 
bacterial colony or colonies, fitness costs associated with 
plasmid transfer and maintaining, adaptive benefits of 
the plasmid (e.g. antibiotic resistance genes), etc. [12, 14, 
18, 20]. It should be noted, however, that if in the course 
of the treatment of an infected patient with a certain an-
tibiotic even a small number of pathogenic bacteria will 
survive by acquiring the resistance to this antibiotic it 
can lead to the death of the patient since the resistant 
bacteria will spread very fast in the body of the patient 
[20]. That is why even if the HGT in bacteria seems to 
be inefficient under certain conditions, it poses a serious 
threat to the health and life of the infected patients. 
Fig. 1. Conjugative plasmid transfer. The bacterium bearing a plasmid (donor) is shown in blue, and the bacterium acquiring a plasmid 
(recipient) is shown in magenta. The plasmid DNA is shown in black. Plasmids are small circular DNA molecules inside the bacterial cell 
that can replicate independently. In the course of conjugation, plasmid-encoded proteins are produced. These proteins assemble into the 
type IV secretion system protein complex that performs several functions: spanning the donor cell envelope, the formation of pilus that 
mediates the contact between the bacterial cells, and the recruitment of the relaxase and a few accessory proteins to the secretion channel. 
In step 1 (nicking), the plasmid-encoded relaxase nicks one strand of the plasmid double-stranded DNA, forming the transfer DNA (T-DNA). 
In step 2 (transfer), the conjugation machinery transports the T-DNA into the recipient cell. In step 3 (DNA synthesis) in the recipient cell, 
the relaxase ligates the 5′- and 3′-ends of the DNA to form a covalently closed single-stranded DNA circle. The complementary DNA strand is 
synthesized to generate a double-stranded DNA circle in the donor and recipient bacteria.
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PLASMID CURING IN BACTERIA 
Since it is widely recognized that the spreading of anti-
biotic resistance in bacteria is accomplished mainly by 
means of HGT,   scientists are focused on studying the 
mechanism of HGT [21] and on searching for methods 
that prevent HGT in bacterial colonies [22]. Research is 
being actively conducted in the following areas: plas-
mid curing compounds, using phages for plasmid curing, 
plasmid curing by CRISPR/Cas system, and incompatibil-
ity-based plasmid curing systems. 
a) Plasmid curing compounds
It has been shown that a number of compounds can be 
used for plasmid curing in vitro [23]. These compounds 
have varying structures, belong to different classes of 
chemical compounds, and consequently have different 
mechanisms of action. In addition, the mechanisms of 
action of some of these compounds are still poorly un-
derstood. Some examples of plasmid curing agents are: 
antibiotics (e.g. quinolones [24]), detergents (e.g. so-
dium dodecyl sulfate [25]), natural compounds derived 
from plants [26], psychotropic drugs and heterocyclic 
compounds [27, 28], etc. Since plasmid conjugation is a 
multistep process (Fig. 1), different compounds disturb 
different steps of this process: some antibiotics (e.g. no-
vobiocin) inhibit the GyrB subunit of bacterial DNA gy-
rase and thereby affect the plasmid DNA supercoiling; 
unsaturated fatty acids prevent transfer of the genetic 
material from the donor cell to the recipient cell [29] 
(step 2, Fig. 1). DNA intercalating agents, such as ethid-
ium bromide [30], acridine orange, and acriflavine [31], 
are used in laboratory studies as efficient plasmid cur-
ing compounds, but have no prospect for practical ap-
plication because of their high toxicity. Phenothiazines – 
compounds that are used as psychotropic drugs – have 
also shown significant plasmid curing activity in vitro 
and are more likely to be used in medical practice in the 
future [27].
b) Phages as plasmid curing agents
As was discussed in recent publications (e.g. [32]), phages 
that target bacterial secretion machinery can effectively 
cure plasmids from bacterial colonies. A bacterium do-
nor uses pilus for the contact with a bacterium recipi-
ent over the course of plasmid transfer by conjugation 
(Fig. 1). Since the pilus targeting phages kill bacteria with 
high pilus expression, it leads to the inhibition of conju-
gation and eventually to plasmid curing. Jalasvuori et al. 
[33] studied the phage targeting the bacterial mating pair 
complex encoded by conjugative plasmids and showed 
that this is another example of bacterial plasmid curing 
by phages.
c) Plasmid curing by CRISPR/Cas system
A number of studies (e. g. [34, 35]) showed that the CRISPR/ 
Cas system can be used for plasmid curing in bacteria. 
CRISPR/Cas, which is also known as the bacterial ‘adap-
tive immune system’, enables bacteria to recognize 
the invading foreign genetic material – DNA or RNA 
sequence – and recruit the corresponding Cas proteins 
for its cleavage. Therefore, the bacterial CRISPR/Cas sys-
tem that targets the DNA of plasmids containing antibi-
otic resistance genes will degrade these plasmids, which 
will eventually prevent the spread of antibiotic resistance 
by plasmid conjugation in the bacterial colony. 
d) Incompatibility-based plasmid curing systems
Investigation of the mechanism of conjugative plasmid 
transfer in bacteria led scientists to the conclusion (e.g. 
[23, 36]) that different plasmids can coexist in the same 
bacterium unless these plasmids share a very similar rep-
lication system. The early exclusion system will prevent 
the uptake of a conjugation plasmid of the same ‘exclu-
sion’ type as the plasmid that bacterium already has. On 
the other hand, under strong selection conditions, the 
entering plasmid displaces the incompatible plasmids 
that are already in this bacterial cell. This approach can 
be used for the eradication of plasmids with antibiotic re-
sistant genes from bacteria by interference plasmids over 
the course of HGT. Kamruzzaman et al. [37] showed that 
plasmid interference can be used for the replacement of 
antibiotic resistance plasmids by the corresponding plas-
mids with deleted antibiotic resistance genes in patho-
genic bacteria in vivo. After that, pathogenic bacteria be-
come susceptible to antibiotics again and infection can 
be cured by the administration of antibacterial drugs. In 
order to achieve the efficient uptake of reference plas-
mids by the bacterial cells that contain the antibiotic re-
sistance plasmids, the authors of this paper used a purify-
ing selection in their experiments (in bacteria and mice). 
Interference plasmids were constructed so that they did 
not carry the antibiotic resistance genes and the toxin-
encoding gene of the original plasmids, but contain the 
same replication system that made them ‘incompatible’ 
with the original antibiotic resistance plasmids. In addi-
tion, another gene, which provides resistance from tet-
racycline, was introduced into the interference plasmids. 
This ensures the high efficiency of uptake of the interfer-
ence plasmids by bacteria (and the further replacement 
of original antibiotic resistance plasmids by these plas-
mids) in the presence of tetracycline because only bac-
teria with interference plasmid containing tetracycline 
resistance gene will survive in these conditions. Since 
interference plasmids did not contain a toxin-antitoxin 
‘addiction’ system, they were cured from bacteria in the 
course of several days and bacteria became susceptible to 
antibiotics including tetracycline. 
HYPOTHESIS
Developing this approach, we came up with a much 
more efficient method of fighting the multidrug resis-
tant bacteria. According to our method [38], in addi-
tion to the tetracycline-resistant gene, the interference 
plasmid contains the antibiotic A encoding gene and 
ligand-dependent transcription factor sequence linked 
to a promoter that is known in the art [39-42]. Since the 
transcription factor for the antibiotic A encoding gene 
is ligand-dependent, the synthesis of antibiotic A is 
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switched off in the presence of a ligand (small molecule 
M1) and switched on in the absence of the ligand. There-
fore, in phase I of treatment, when the colony of multi-
drug resistant bacteria is exposed to tetracycline and small 
molecule M1 in the presence of this interference plasmid, 
in order to survive the bacteria have to uptake the inter-
ference plasmid because, otherwise, it will be killed by 
tetracycline. On the other hand, since small molecule M1 
is administered at the same time, the synthesis of antibi-
otic A from the interference plasmid is blocked. In phase 
II of treatment, tetracycline is administered without small 
molecule M1. Therefore, in these conditions, the synthe-
sis of antibiotic A begins from the interference plasmid, 
which now is in every bacterial cell that leads to the rapid 
death of bacteria. In case the bacteria lose the interference 
plasmid, they will be killed by tetracycline because only 
the presence of this plasmid containing the tetracycline 
resistant genes ensures the protection of the bacteria from 
this antibiotic. Therefore, this approach will lead to fast 
cures from the colonies of pathogenic bacteria. 
The well-known tetracycline-controlled gene ex-
pression system, which is successfully employed for the 
upregulation [43, 44] and downregulation [45] of gene 
expression, can be used in this kind of interference plas-
mids. Then, in phase I in the presence of tetracycline, 
only bacteria that accepted interference plasmid will 
survive (because the interference plasmid contains tet-
racycline resistance gene and at the same time in the 
presence of tetracycline antibiotic A synthesis is blocked 
(tetracycline downregulation scheme)). In phase II, when 
the administration of tetracycline is stopped and all the 
bacteria contain the interference plasmid, the synthe-
sis of antibiotic A, encoded by the interference plasmid, 
is started that leads to the rapid extermination of the 
pathogenic bacterial colony. Tetracycline can be used in 
the upregulation scheme also if in the first step a differ-
ent antibiotic is used and the synthesis of antibiotic A in 
the second step is started by the administration of tetra-
cycline. Naturally, other antibiotics can be used instead 
of tetracycline in this method. 
The synthesis of an antibiotic encoded by plasmid in-
side the bacterial cell has several significant advantages 
compared with oral or intravenous antibiotic administra-
tion:
• The amount of antibiotic necessary to kill bacteria in 
this case is much smaller because it is not spread in 
the bloodstream but is synthesized in the bacterial cell;
• It should not be delivered to the bacterial colony by 
the bloodstream;
• An antibiotic synthesized in the bacterial cell will act 
right away that  significantly reduces the possibility 
of any side reactions at physiological pH;
• The molecule of this antibiotic should not have the 
special physicochemical properties necessary for 
penetration into the bacterial cell through the mem-
brane (or membranes) and bacterial cell wall;
• Because of the above-mentioned advantages, the 
probability of side effects from this antibiotic is neg-
ligible.
It is known that bacteria are adapting very fast to any 
changes in the environment, including the presence of 
antibiotics, but this approach will give bacteria practical-
ly no time to come up with a new resistance mechanism.
Recently, the lytic bacteriophages cycle and especially 
the action of phage-derived lytic proteins – holins, en-
dolysins, and spanins – draw the close attention of the 
scientific community in connection with the develop-
ment of new approaches to fight the pathogenic bacte-
ria [46]. Holins and endolysins are used in the last stage 
of the phage lytic cycle to release the progeny from the 
bacterial cell: holins form the pores in the inner bacterial 
membrane and release endolysins that destroy the bacte-
rial cell wall. Currently, the discussion is ongoing in the 
scientific literature about the possibility of using these 
proteins as antimicrobial agents [47]. On the other hand, 
these proteins are already used in a number of processes 
in biotechnology [48], e.g. for breaking-up the bacterial 
membrane and cell wall in order to release the product 
of fermentation [49-51]. In fact, it was shown recently 
that holins and endolysins encoded by the corresponding 
plasmids could be synthesized in the bacterial cell that 
inevitably leads to bacterial cell lysis. The synthesis of 
these proteins and consequently the bacterial cell lysis 
was induced by xylose, by the reduced concentration of 
Mg2+ ions, or 3-methylbenzoate [49]. On the other hand, 
Borrero-de Acuna et al. [52] developed an efficient induc-
ible lytic system for the Gram-negative bacteria using 
the lysozyme encoding plasmid.
Therefore, the interference plasmids encoding holins 
and endolysins (instead of antibiotic A) can be used for 
fighting the pathogenic bacteria using the above-described 
approach. In this case, after the interference plasmid will 
be acquired by the pathogenic bacteria, the synthesis of 
holins and endolysins will be activated by the administra-
tion of the corresponding ligand (e.g. xylose) leading to 
the fast lysis of the bacterial cell. This process also has one 
important advantage – bacterial resistance to the phage 
lysins is an extremely rare event [53] – e.g. no resistance 
to the action of endolysins has been reported to date [54]. 
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